Commercialization News

If you’re looking to stay up to date with the latest commercialization news out of the Office of Research and Technology Management at Case Western Reserve University, you’ve come to the right place. Explore some of our latest headlines relating to inventions, startups and more from researchers at CWRU.


2023

Any Target, Every Time - How molecular “matchmaking” could pave the way for drug development to target the 85% of molecules considered undruggable.
Amgen.com | Nov. 28, 2023

Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
Luciddx.com | Oct. 31, 2023

NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
Nervgen.com | Oct. 23, 2023

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Nervgen.com | Sept. 25, 2023

When a Network Matters! Functional iPSC-derived Endothelial Cells Finally Arrive
Bioinformant | Sept. 18, 2023

‘Great news for patients:’ Breathing device from UH, CWRU to help more paralyzed patients
Cleveland.com | July 25, 2023

Two NE Ohio startups land Ohio Third Frontier grants
Crain's Cleveland Business | July 11, 2023

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
PAVmed | May 11, 2023

Biomarkers and Balloons Help in the Fight Against Esophageal Cancer
AUTM | April 21, 2023

Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
PAVmed | April 18, 2023

NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
NervGen | April 13, 2023

NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
NervGen | March 30, 2023

Biohm partners with Life Extension to design targeted microbiome supplements
NutraIngredients USA | March 16, 2023

CWRU creates company to market its HoloAnatomy software that teaches cadaver-free anatomy
Cleveland.com | March 15, 2023

Case Western Reserve University completes exclusive license agreement with Atlanta-based RORA Biologics Inc. for cancer and HIV therapy technologies
The Daily | March 8, 2023

BIOHM Probiotic Products Gain Investment from Valley Growth Ventures
The Business Journal Daily | March 8, 2023

Case Western Reserve University completes exclusive license agreement with Atlanta-based RORA Biologics Inc. for cancer and HIV therapy technologies
The Daily | Feb. 23, 2023

CWRU reaches international licensing deal with Atlanta company
Crain's Cleveland Business | Feb. 23, 2023

Lucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event
PAVmed | Feb. 15, 2023

National Academy of Inventors names eight Case Western Reserve University researchers to 2023 class of senior members
The Daily | Feb. 14, 2023

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen | Feb. 14, 2023

Bringing ideas to market: CWRU researchers turn discoveries into inventions
The Daily | Feb. 13, 2023

St. Joseph students studying anatomy in virtual reality
Fox 8 WJW | Feb. 7, 2023

This Week In XR: $18 Million For Gemba VR Training, Dreamscape Learn Spins Off With $20 Million
Forbes | Jan. 27, 2023

$578 million for Greater Cleveland’s startups: These 23 companies raised the most cash in 2022
The Plain Dealer | Jan. 26, 2023

New company from Case Western Reserve University helps medical students learn anatomy through holographic imagery
Ideastream Public Media | Jan. 26, 2023

Making blood in the lab: Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.
Drug Discovery and Development | Jan. 18, 2023

Case Western Reserve University launches Ilumis: Startup to accelerate and scale adoption of pioneering HoloAnatomy software to transform the way students learn human anatomy
The Daily | Jan. 17, 2023


2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
Lucid Diagnostics | Dec. 8, 2022

Researchers Markowitz, Tyler elected fellows for 2022 class of National Academy of Inventors
The Daily | Dec. 8, 2022

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
Lucid Diagnostics | Dec. 1, 2022

Exclusive license agreement with Case Western Reserve University for Core-NK platform
Chimeric Therapeutics | Nov. 21, 2022

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
PAVmed | Dec. 1, 2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
PAVmed | Dec. 8, 2022

Researchers Markowitz, Tyler elected fellows for 2022 class of National Academy of Inventors
The Daily | Dec. 8, 2022

Case Western Reserve University receives $1M state grant for technology start-up fund
The Daily | Nov. 21, 2022

Third Frontier Provides Funds to Accelerate Innovation
Ohio Department of Development | Oct. 18, 2022

NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
NervGen | Oct. 25, 2022

A ‘game changer’ for people with sickle cell disease: Case Western Reserve University researcher, company, collaborating to develop blood test measuring the effects, potency of new gene therapies for sickle cell disease
The Daily | Sept. 14, 2022

Top faculty to be honored during CWRU’s inaugural Innovation Week
The Daily | Sept. 8, 2022

An inventive spirit, an impressive ranking
The Daily | Sept. 8, 2022

A ‘game changer’ for people with sickle cell disease
The Daily | Sept. 9, 2022

Folio Photonics Announces Breakthrough Multi-Layer Optical Disc Storage Technology to Enable Industry-Disruptive Cost, Cybersecurity and Sustainability Benefits
Folio Photonics | Aug. 30, 2022

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
PAVmed | Aug. 11, 2022

NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update
NervGen | Aug. 10, 2022

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
Lucid Diagnostics | Aug. 4, 2022

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
BusinessWire | Aug. 3, 2022

NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference
NervGen | Aug. 2, 2022

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
PAVmed | Aug. 2, 2022

NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors
NervGen | July 14, 2022

RAD adds brain tumor technology to portfolio
Radiopharm Theranostics | June 9, 2022

Case Western Reserve University signs license agreement to bring artificial intelligence breakthroughs closer to cancer patient care
The Daily | May 25, 2022

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
AccessWire | May 12, 2022

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
PAVmed | May 9, 2022

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
PAVmed | April 4, 2022

NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
NervGen | March 31, 2022

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
PAVmed | March 24, 2022

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
PAVmed | March 23, 2022

NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
NervGen | March 15, 2022

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
PAVmed | March 3, 2022

Three Case Western Reserve University faculty elected as 2022 Senior Members of National Academy of Inventors
The Daily | Feb. 11, 2022

Case Western Reserve University grants exclusive license to Ionis Pharmaceuticals to advance antisense therapy for Pelizaeus-Merzbacher disease
The Daily | Jan. 27, 2022

Road-painting robot created in Northeast Ohio could save lives
News 5 Cleveland | Jan. 21, 2022

Case Western Reserve University partners with Produce Perks Midwest, expanding nutrition-incentive technology at farmers’ markets
The Daily | Jan. 20, 2022

CWRU On Track

Crain's Cleveland Business | Jan. 20, 2022

CWRU inks licensing deal to commercialize an imaging agent to aid in brain tumor surgery
Crain's Cleveland Business | Jan. 19, 2021

Cleveland-based RoadPrintz Inc. receives $1M from National Science Foundation to advance mobile robotic pavement-marking system

The Daily | Jan. 5, 2022


2021

NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
NervGen | Dec. 22, 2021

Zheng-Rong Lu elected fellow of National Academy of Inventors
The Daily | Dec. 22, 2021

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
PAVmed | Dec. 1, 2021

Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform
Global NewsWire | Nov. 30, 2021

NervGen Pharma Corp. Closes Non-Brokered Private Placement
NervGen | Nov. 29, 2021

First Point-of-Care Test for Serious Hemoglobin Disorder, Beta Thalassemia, Provides New Weapon for the Front Lines of Healthcare Worldwide
Hemex Health | Nov. 24, 2021

NervGen Pharma Reports Third Quarter 2021 Results
NervGen | Nov. 18, 2021

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics | Nov. 11, 2021

NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021
NervGen | Nov. 4, 2021

Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
Lucid Diagnostics | Oct. 28, 2021

Case-Coulter Translational Research Partnership, with support provided by JobsOhio for the Cleveland Innovation District, awards $1.9 million in funding and support for promising biomedical engineering university technologies
The Daily | Oct. 20, 2021

NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
NervGen | Oct. 18, 2021

Lucid Diagnostics Announces Pricing of Initial Public Offering
PAVmed | Oct. 13, 2021

Peak Nanosystems raises $25 million from Squadron Capital
Crain's Cleveland Business | Oct. 8, 2021

NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trails
NervGen Pharma | Sept. 27, 2021

Lucid Diagnostics, a medtech company with ties to Case Western Reserve University, plans to go public
Crain's Cleveland Business | Sept. 24, 2021

PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
PAVmed | Sept. 23, 2021

Lucid Diagnostics prepares to leave the PAVmed nest with $57M IPO filing
Fierce Biotech | Sept. 23, 2021

PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MyStrategist.com/MedTech-Strategist | Aug. 19, 2021

PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
Business Wire | Aug. 10, 2021

Nervgen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer’s Disease
Business Insider | Aug. 9, 2021

PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MedTech Strategist | Aug. 2, 2021

Breakthrough Device ClotChip Moves Forward Toward Production
PRNewswire | July 22, 2021

Case Western Reserve University Licenses Rapid Malaria, Hemoglobin Disorder Tests
AUTM | July 16, 2021

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System
Neuros Medical | June 29, 2021

Presidio Medical Announces New Executive Appointment
BusinessWire | June 28, 2020

NervGen Pharma: A “Blockbuster Drug” in the Making?
Stockhouse | June 28, 2021

Third Frontier awards more than $9 million in funding for Northeast Ohio
TechOhio, June 24, 2021

Case Western Reserve ranks 21st in the world for U.S. utility patents
The Daily | June 15, 2021

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
PAVmed | June 10, 2021

NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer’s Disease Models
NervGen | June 10, 2021

MedLumics Closes Upsized (21.7M USD) Financing Round and Appoints New Chairman
MedLumics | May 28, 2021

PAVmed  Subsidiary  Lucid  Diagnostics Receives  CE  Mark  Certification  for  its EsoCheck®  Esophageal  Cell  Collection Device
PAVmed | May 26, 2021

NervGen Pharma Reports First Quarter 2021 Results
NervGen | May 20, 2021

A Quiet Student Startup Bursts Into the Big Time as Path Robotics Attracts $56 Million In New Investment
The Daily | May 7, 2021

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-29
NervGen | May 6, 2021

Case Western Reserve University-Developed Imaging Agent for MRI Prostate Cancer Detection Gets FDA Approval for Safety Trails, Set to Begin This Month in Columbus
The Daily | May 5, 2021

Ohio Third Frontier Commission bolsters Case Western Reserve University startup funding
The Daily | April 29, 2021

FDA Approves Tumor-Based MRI Contrast Agent for Prostate Cancer Detection
Diagnostic Imagining | April 25, 2021

NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
NervGen Pharma | April 22, 2021

First Clinical Trials Set for MRI Cancer Detection
Eurek Alert | April 22, 2021

CWRU Atelerix Sign Option License to Develop Therapeutic Approach to Opioid Crisis
Crain's Cleveland Business | April 20, 2021

Team players: Cleveland Innovation District is a group effort for local healthcare investment

FreshWater Cleveland | April 22, 2021

Cardialen Announces Positive Results From Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation
Business Wire | April 13, 2021

Journey to multi-million dollar Amgen acquisition required curiosity, collaboration and commercial expertise
The Daily | April 8, 2021

Case Western Reserve University biotech startup Rodeo Therapeutics Corp. sold to Amgen Inc.
The Daily | March 31, 2021

Amgen to Acquire Rodeo Therapeutics Corporation
PRNewswire | March 30, 2021

Preclinical Program Targeting 15-PGDH has Potential use in Broad Range of Therapeutic Applications Including Inflammatory Disease Indications
The PharmaLetter | March 30, 2021

Equalize 2021 Pitchers Announced
Equalize | Feb. 18, 2021

NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
NervGen | March 8, 2021

NervGen Pharma Provides Regulatory Update on Development Program for NVG-291
NervGen | March 2, 2021

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Result
PAVmed | Feb. 22, 2021

Rohan Akolkar Elected Senior Member of National Academy of Inventors
The Daily | Feb. 11, 2021

NervGen Pharma Adds Alzheimer’s Disease Patient Cohort to its Phase 1 Clinical Trial Program
NervGen | Jan. 27, 2021

NervGen’s 2020 in Review and the Plan Ahead
NervGen | Jan. 11, 2021

Neuros Medical Announces Key Milestones in the Quest Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical | Jan. 6, 2021

Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical | Jan. 6, 2021

Tevard, Zogenix Partner to Advance Gene Therapies for Genetic Epilepsies
Dravet Syndrome News | Jan. 5, 2021

NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
NervGen Pharma | Jan. 5, 2021

2020

Global Health Breakthroughs – other than for COVID-19 in 2020
Devex | Dec. 22, 2020

NervGen Pharma Engages CRO for Phase 1 Clinical Trial

NervGen | Dec. 15, 2020

Case-Coulter Translational Research Partnership Awards $1.1 Million in Funding and Support for Promising Biomedical Engineering University Technologies
The Daily | Dec. 14, 2020

Case Western Reserve University biomedical engineering leaders Scott Bruder, Anant Madabhushi honored for ‘spirit of innovation’

The Daily | Dec. 8, 2020

Tevard Biosciences, Zogenix partner on tRNA-based Gene Therapies
The Science Advisory Board | Dec. 4, 2020

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies
Tevard Biosciences | Dec. 3, 2020

NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
NervGen Pharma | Nov. 19, 2020

Neuros Medical is Raising $42.8 Million
Crain’s Cleveland Business | Nov. 11, 2020

Team of Case Western Reserve University Researchers to Study Plastic Recycling Thanks to $2.5M Grant
News 5 Cleveland | Nov. 10, 2020

Trailhead Biosystems Raises $6.6 Million in Series A Financing
Trailhead Biosystems Inc. | Nov. 10, 2020

NervGen Retains Dr. George Perry to Advise on Alzheimer’s Disease Program
NervGen Pharma | Nov. 10, 2020

NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291
NervGen | Oct. 19, 2020

VA, CWRU Researchers Create Smart Bandage to Improve Wound Care for Veterans
News 5 Cleveland | Oct. 12, 2020

HEMEX Health’s “Gazelle” earns third prize in NIH Technology Accelerator Challenge
The Daily | Oct. 9, 2020

Diaphragm Pacing can Enhance Recovery and Weaning from Mechanical Ventilation (MV) in Cardiac Surgery
PR Newswire | Oct. 1, 2020

NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
NervGen | Oct. 1, 2020

Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases
The Daily | Aug. 31, 2020

NervGen Pharma Reports Second Quarter 2020 Results Phase 1 Clinical Study Remains on Track for Q4 2020
NervGen | Aug. 21, 2020

PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
Global NewsWire | Aug. 18, 2020

Scientists work to freeze-dry synthetic platelets
The Daily | Aug. 12, 2020

Umut Gurkan elected senior member of National Academy of Inventors
The Daily | Aug. 11, 2020

NervGen Pharma Corp. Completes $6.45 Million Public Offering
NervGen | Aug. 10, 2020

PAVmed Secures $7 Million Convertible Note Financing
Global NewsWire | Aug. 6, 2020

https://www.nervgen.com/2020/07/nervgen-pharma-announces-pricing-of-public-offering/
NervGen | July 27, 2020

Case Western and VA partner with Pennsylvania start-up to commercialize adjustable walker
Tech Transfer Central | July 15, 2020

Presidio Medical Announces $30 Million Financing Round Led by Invus Opportunities
Presidio | July 14, 2020

LevelMed signs agreement to commercialize self-leveling walker
TechLink | July 13, 2020

Haima Therapeutics Receives Phase II TVSF Award from the State of Ohio to Develop its SynthoPlate Product for Veterinary Use
Haima Therapeutics press release | July 9, 2020

Luminary Therapeutics and Case Western Reserve University Enter Formal Collaboration for Development of BAFF CAR
EIN Presswire | July 7, 2020

Akouos Announces Closing of Initial Public Offering
Globe NewsWire | June 30, 2020

Third Frontier awards $2.4 million to Northeast Ohio universities and companies
Crain's Cleveland Business | June 29, 2020

Advancing Cutting-Edge Technology in Ohio: Third Frontier Accelerating New Ideas and Solutions
Ohio Development Services Agency | June 24, 2020

XaTek to develop rugged ClotChip for U.S. Navy
PR Newswire | June 23, 2020

CWRU researchers develop technology to recycle plastic waste from cars, planes, industry
News 5 Cleveland | June 23, 2020

NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
NervGen Pharma press release | June 22, 2020

CWRU completes license option with spinout company Edifice Analytics
Crain's Cleveland Business | June 19, 2020

New, Quick Test For Sickle Cell Disease Comes Online
Ideastream | June 19, 2020

Case Western Reserve Completes License Option with Spinout Company Edifice Analytics Inc
The Daily | June 18, 2020

A New Weapon in the Fight Against Sickle Cell Disease
The Daily | June 18, 2020

'Optimized for the underserved': A new diagnostic test built for low-income settings
Devex | June 17, 2020

Gazelle™ Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies with AI to Transform Disease Screening and Diagnosis
Hemex Health press release | June 16, 2020

Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor

PAVmed | June 15, 2020

PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard Esophageal DNA Test

GlobeNewswire | June 11, 2020

Haima Therapeutics Licenses Synthetic Platelet Technology from Case Western Reserve University for Hemostatic Therapy
The Daily | June 3, 2020

Top 100 Worldwide Universities Granted U.S. Utility Patents in 2019 Announced

National Academy of Investors | June 2, 2020

New Technology Gives Patients Access to a 5-Minute, Office-Based Test to Identify Risk for Esophageal Cancer
National Cancer Institute | June 1, 2020

NervGen Pharma Reports First Quarter 2020 Results - Phase 1 Clinical Trial Remains on Track
NervGen Pharma Corp. press release | June 1, 2020

RoadPrintz Inc., with technology created at CWRU, secures additional funding to advance robotic street-painting vehicle
The Daily | May 26, 2020

RoadPrintz and Case Western Reserve University Testing Robotic Pavement Marking Machine
ForConstructionPros | May 20, 2020

Medical Device Developed by CWRU/UH Researchers Wins 2020 Edison Award
The Daily | May 1, 2020

First successful field evaluation of new, one-minute haemozoin-based malaria diagnostic device
Elsevier press release | April 24, 2020

Peak Nanosystems Raises $25mm Series C Round to Fund Acquisition and Expand Product Lines
The Moore County News Press | April 14, 2020

XaTek Inc. Receives FDA’s “Breakthrough Devices Designation” for CWRU-Licensed ClotChip Technology
The Daily | April 2, 2020

PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
GlobeNewswire | April 2, 2020

First successful field evaluation of new, one-minute haemozoin-based malaria diagnostic device
Elsevier press release | April 2, 2020

XaTek Inc. Receives Key FDA Designation to Aid Commercialization of its ClotChip Device
Crain's Cleveland Business | March 3, 2020

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
PAVMed Inc. | Feb. 11, 2020

Local Inventors Create Prototype That Can Make Painting Roads Safer, Less Expensive
WJW FOX 8 News Cleveland | Jan. 29, 2020

CWRU Hopes a Local Company is on the Road to Producing a Safer, Faster Painting System
Crain's Cleveland Business | Jan. 23, 2020

University’s HoloAnatomy Spreads to Other Campuses
The Daily | Jan. 22, 2020

CWRU and RoadPrintz Inc. Sign License Agreement to Advance Robotic Street-Painting Technology
The Daily | Jan. 21, 2020

Releasing the Handbrake on Endogenous Repair – An Alternative Approach to Treating Alzheimer’s Disease? (An interview with NervGen Pharma President and CEO, Paul Brennan)
Technology Networks | Jan. 13, 2020